Summary: A new digital PCR instrument with two different sample throughput formats (24 and 96), many more partitions, and more…
Five years and seven months ago (March 2012) the Next Generation Technologist blog had a set of four goals: An…
Executive “TL;DR” Summary: An interesting platform called SlipChip with potential point-of-care applications, for fast and potentially very inexpensive digital PCR…
What will you do with 1000-fold improvement in sensitivity over standard immunoassays? What about 100-fold improvement in sensitivity over Luminex…
“Amateurs focus on identifying their weakness and improving them. Professionals focus on their strengths and on finding people who are…
“Keep working no matter what happens If things are good, keep working. If things are bad, keep working.” Moby (American…
A two-year stint at SeraCare comes to an end A little over two years ago I wrote a post called…
What happens when commercial interests do not align? Over a decade ago in 2002 when Novartis announced it was moving…
There is a numbers problem, and a biomarker one as well. Annually the worldwide cancer drug market is on the order of…
A ‘gold rush’ multi-billion dollar business, three targets, four cancer drugs, four antibody-based companion diagnostic tests, sixteen FDA approvals The…